MedTrace Logo

Neuroinflammation and Cognitive Decline in Alzheimer Disease

NCT02377206 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2022-09-14

No results posted yet for this study

Summary

The purpose of this study is to assess the level of neuroinflammation in Alzheimer Disease subject (mild to moderate) estimated with Binding Potential (BP) of \[18F\]DPA-714, and its relationship with the kinetics of cognitive decline over a 24-month follow-up period (as assessed by Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-Cog) and Mini-Mental State Examination (MMSE) scores).

Conditions

  • Alzheimer Disease

Interventions

OTHER

ADAS-Cog evaluation

\[18F\]DPA-714 PET imaging

Sponsors & Collaborators

  • University Hospital, Tours

    lead OTHER

Principal Investigators

  • Vincent CAMUS, PhD · University Hospital of Tours

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-04-06
Primary Completion
2019-12-04
Completion
2019-12-04

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02377206 on ClinicalTrials.gov